
Bariatric Surgery is effective to induce significant weight loss after GLP-1 failure
Bariatric surgery is effective rescue strategy after GLP-1 receptor agonist failure medicalxpress.com/news/2026-…

Professor of Metabolic Surgery, Director Metamor Institute, Pennington Biomedical Research Center of Louisiana State University

Bariatric Surgery is effective to induce significant weight loss after GLP-1 failure
Bariatric surgery is effective rescue strategy after GLP-1 receptor agonist failure medicalxpress.com/news/2026-…

Join us TOMORROW at 8PM, ET for #ASMBS Bariatric Happy Hour, featuring Walter J. Pories, MD, and bariatric fellow Courtney Whitelock, MD as they revisit a landmark paper and its continued relevance to the field today. Register here to join: buff.ly/JCjf37D #Health

2025IFSO's position statement reflects this. @TheLancetEndo Cohen RV et al International Federation for the Surgery of Obesity statement on metabolic bariatric surgery after pharmacotherapy-induced weight loss in clinical obesity doi.org/10.1016/S2213-8587(2…
When GLP-1s Fall Short, Bariatric Surgery Can Deliver Substantial Weight Loss consultqd.clevelandclinic.or… via @clevelandclinic @CleClinicMD @ObesityWeek @ObesitySociety @EASOobesity @ASMBS @AnnalsofSurgery #ObesityWeek #OW2026

Proud to be part of the #JAMASummit on #obesity and the #JAMASummit Report! Been treating patients with obesity for many years and so gratifying to see entire House of Medicine involved in addressing obesity
The #JAMASummit Report on #Obesity identifies 3 broad targets for action: preventing obesity at the societal level, improving care for individuals living with obesity, and strengthening research and innovation. The report indicates that no single intervention is likely to be sufficient, including medication alone. Authored by more than 50 multidisciplinary experts from around the world, the report synthesizes insights from the JAMA Summit on Obesity and outlines priority actions to address one of the world’s most significant health challenges. 🔗 Read the full report: ja.ma/4t9nTrg #ObesityWeek #OW2026

At #ObesityWeek: The world for young persons with obesity will change because of SURMOUNT-ADOLESCENTS. More than half of teens no longer had a BMI in the range of obesity after 72 weeks of tirzepatide. #OW2026 HT: @EliLillyandCo conscienhealth.org/2026/11/1…


Preclinical obesity: excess adiposity, organs still working normally. In a Nature study of four cohorts, about 70-90% of people with it remained stable over a decade. The cartoon is a dramatization; BMI stays, paired with waist measures. MBS Digest Issue 19. Link in reply.

Clinical vs preclinical obesity in 844,108 adults from China, UK, USA and Spain (Nature): pooled mortality HR 1.69 for clinical and 1.19 for preclinical obesity, vs neither obesity nor organ dysfunction. Observational. Article of the Week, MBS Digest Issue 19. Link in reply.

MBS Digest N.º 19 (en español), Artículo de la Semana: en 844.108 adultos de China, Reino Unido, EE. UU. y España (Nature), HR de mortalidad agrupado de 1,69 para la obesidad clínica y 1,19 para la preclínica; estudio observacional. Enlace en la respuesta.

Sleep & Diabetes Most adults need about 8 hours of sleep. Too little or too much can harm your health. Poor sleep is linked to higher diabetes risk and worse blood sugar control. Better sleep = better health. Learn more: mediflix.com/topics/diabetes #AmericanDiabetesMonth

SYNCHRONIZE CVOT Cardiovascular safety for the GCGR-GLP-1R co-agonist survodutide yet lingering tolerability issues highlight need for more flexibe dosing going forward thelancet.com/journals/lance…


New on The Staple Line, the weekly audio edition of MBS Digest. Vol. 2, No. 18: cirrhosis that regressed after bariatric surgery, surgery after GLP-1 drugs fall short, heart and kidney outcomes, and retatrutide for knee pain, each with its catch. Link in reply.

On this week's Staple Line, in my own voice: thirty selected patients whose cirrhosis regressed after bariatric surgery, read three ways and with no comparison group; what happens when GLP-1 drugs fall short; and retatrutide's benefits alongside its side effects. Link in reply.

The obesity adverse outcome story. BMI is a poor and misleading way to quantify obesity When the CAD-obesity definition is used, we see the increased risk of all-cause mortality (top graphs) and lesser risk for preclinical obesity (lower graphs) @Nature nature.com/articles/s41586-0…

Paired biopsies a median 6.2 years apart: cirrhosis regressed in 33% of 30 patients with compensated MASH cirrhosis after bariatric surgery. Small and selected, no nonsurgical comparator, so an association. Article of the Week, MBS Digest Issue 18. Link in reply.